Aprecia Pharmaceuticals, a Blue Ash, Ohio-based specialty pharmaceutical company using its proprietary 3D printing technology platform to develop and manufacture pharmaceuticals, raised $35m in funding.
The round was led by Deerfield Management Company, which invested $30m.
The company intends to use the funds to launch SPRITAM®, a 3D printed medicine approved by the U.S. Food and Drug Administration, as well as accelerate the development of additional 3D printed drug formulations utilizing its novel 3DP technology platform.
Led by Don Wetherhold, CEO, Aprecia expects to use its proprietary ZipDose three-dimensional printing (3DP) technology to develop and manufacture pharmaceutical products on a commercial scale. The company’s initial focus is on the central nervous system therapeutic area including SPRITAM, an oral fast-melt form of levetiracetam for epilepsy.